A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

NCT04684394 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

50

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Neovascular Age-related Macular Degeneration
Retinal Disease
Retinal Degeneration
Macular Degeneration

Interventions

BIOLOGICAL: GEM103
DRUG: Aflibercept
DRUG: Sham

Sponsor

Gemini Therapeutics, Inc.